Glenmark Pharmacueticals Ltd.'s net profit for the fourth quarter of FY26 jumped sharply by nearly 64 times year-on-year, according to an exchange filing on Friday.
The Pharma giant posted a consolidated bottom-line of Rs 301 crore, compared to Rs 4.7 crore in the year-ago period. Revenue from operations jumped 15.8% to 3,771 crore in the quarter under review from Rs 3,256 crore.
Growth on the operational front remained strong as earnings before interest, taxes, depreciation and amortisation surged 36% to Rs 763 crore from 561 crore in the corresponding quarter of the last fiscal.
Ebitda margin expanded to 20.2% from 17.2% in the comparable quarter.
Additionally, the firm has declared a final dividend of Rs 2.5 per share with face value of Rs 1 on the Equity Share Capital of the Company for the financial year 2025-26.
Follow all the earnings live updates here.
Glenmark Pharma Q4 Result Highlights (Cons, YoY)
- Net Profit at Rs 301 crore versus Rs 4.7 crore
- Revenue up 15.8% at Rs 3,771 crore versus Rs 3,256 crore
- Ebitda up 35.9% at Rs 763 crore versus Rs 561 crore
- Ebitda Margin at 20.2% versus 17.2%
- To pay dividend of Rs 2.5 per share
ALSO READ: IndiGo Q4 Results: Airline Swings To Loss After Rs 4,823 Crore Forex Hit
Glenmark Pharma Share Price
The stock settled 4.61% lower at Rs 2,274.90 apiece on the NSE. This compared to a 1.5% decline in the benchmark Nifty index on Friday. The scrip has risen 11.78% year-to-day and 61.75% in the last 12 months.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
